JP2004526723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004526723A5 JP2004526723A5 JP2002571053A JP2002571053A JP2004526723A5 JP 2004526723 A5 JP2004526723 A5 JP 2004526723A5 JP 2002571053 A JP2002571053 A JP 2002571053A JP 2002571053 A JP2002571053 A JP 2002571053A JP 2004526723 A5 JP2004526723 A5 JP 2004526723A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- drug according
- concomitant drug
- directed
- concomitant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drugs Drugs 0.000 claims 10
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 229940000425 combination drugs Drugs 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 239000002858 neurotransmitter agent Substances 0.000 claims 2
- 230000001242 postsynaptic Effects 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 102000015554 Dopamine receptor family Human genes 0.000 claims 1
- 108050004812 Dopamine receptor family Proteins 0.000 claims 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical group C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- 230000000561 anti-psychotic Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 230000030214 innervation Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Claims (11)
- 所与の神経伝達物質に特異的なシナプス後受容体を少なくとも部分的に遮断する第一の物質と、
神経伝達物質に起因する神経支配の求心路遮断を開始または促進する第二の物質としてアンフェタミン誘導体とを含むパーキンソン病治療用併用薬。 - 第一の物質がシナプス後ドーパミン受容体を遮断する物質であることを特徴とする請求項1に記載の併用薬。
- 第一の物質がドーパミン拮抗薬であることを特徴とする請求項1または2に記載の併用薬。
- 第一の物質が抗精神病薬であることを特徴とする請求項1から3のいずれか一項に記載の併用薬。
- 第一の物質がハロペリドールであることを特徴とする請求項1から4のいずれか一項に記載の併用薬。
- 第二の物質が、神経細胞(特にドーパミン細胞)において酸化的ストレスを増大させる物質であることを特徴とする請求項1から5のいずれか一項に記載の併用薬。
- 第二の物質がメタアンフェタミンであることを特徴とする請求項1から6のいずれか一項に記載の併用薬。
- 指示通りに使用する場合、第一の物質を第二の物質より先に使用することを特徴とする請求項1から7のいずれか一項に記載の併用薬。
- 指示通りに使用する場合、第一の物質および/または第二の物質を複数回使用することを特徴とする請求項1から8のいずれか一項に記載の併用薬。
- 指示通りに使用する場合、第一の物質および/または第二の物質を経口および/または皮下および/または静脈内および/または腹腔内投与で使用することを特徴とする請求項1から9のいずれか一項に記載の併用薬。
- パーキンソン病の症状に関して予防的に使用できることを特徴とする請求項1から10のいずれか一項に記載の併用薬。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10111486A DE10111486A1 (de) | 2001-03-09 | 2001-03-09 | Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit |
PCT/EP2002/002571 WO2002072094A2 (de) | 2001-03-09 | 2002-03-08 | Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004526723A JP2004526723A (ja) | 2004-09-02 |
JP2004526723A5 true JP2004526723A5 (ja) | 2005-12-22 |
Family
ID=7676934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002571053A Pending JP2004526723A (ja) | 2001-03-09 | 2002-03-08 | パーキンソン病治療用の神経活性物質の使用および併用薬 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040147613A1 (ja) |
EP (1) | EP1377294B1 (ja) |
JP (1) | JP2004526723A (ja) |
KR (1) | KR20040007464A (ja) |
AT (1) | ATE320810T1 (ja) |
AU (1) | AU2002254935A1 (ja) |
DE (2) | DE10111486A1 (ja) |
DK (1) | DK1377294T3 (ja) |
ES (1) | ES2261663T3 (ja) |
PT (1) | PT1377294E (ja) |
WO (1) | WO2002072094A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007016190A2 (en) * | 2005-07-28 | 2007-02-08 | Duke University | Antiparkinsonian action of phenylisopropylamines |
KR20120103557A (ko) * | 2009-07-31 | 2012-09-19 | 클레라 아이엔씨. | 파킨슨씨병 치료용 조성물 및 치료방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU77658A1 (de) * | 1977-06-30 | 1979-03-26 | Byk Gulden Lomberg Chem Fab | Alkylsubstituierte piperidin-n-oxide,verfahren zu ihrer herstellung,ihre verwendung und sie enthaltende arzneimittel |
US5602150A (en) * | 1992-10-02 | 1997-02-11 | Research Foundation For Mental Hygiene, Inc. | Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia |
AU1129295A (en) * | 1993-01-06 | 1996-05-23 | Neurogen Corporation | Certain tricyclic substituted diazabicyclo{3.2.1} octane derivatives |
CA2195239A1 (en) * | 1994-07-15 | 1996-02-01 | David E. Nichols | Optically active isomers of dihydrexidine and its substituted analogs |
KR20000057303A (ko) * | 1996-12-24 | 2000-09-15 | 후지야마 아키라 | 아미노피페라진 유도체의 신규 용도 |
EP1042004A4 (en) * | 1997-12-31 | 2004-08-25 | Direct Therapeutics Inc | METHOD FOR TISSUE PERFUSION |
CA2380953A1 (en) * | 1999-08-18 | 2001-02-22 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
-
2001
- 2001-03-09 DE DE10111486A patent/DE10111486A1/de not_active Withdrawn
-
2002
- 2002-03-08 DE DE50206139T patent/DE50206139D1/de not_active Expired - Fee Related
- 2002-03-08 DK DK02724212T patent/DK1377294T3/da active
- 2002-03-08 KR KR10-2003-7011884A patent/KR20040007464A/ko not_active Application Discontinuation
- 2002-03-08 US US10/469,833 patent/US20040147613A1/en not_active Abandoned
- 2002-03-08 PT PT02724212T patent/PT1377294E/pt unknown
- 2002-03-08 ES ES02724212T patent/ES2261663T3/es not_active Expired - Lifetime
- 2002-03-08 AU AU2002254935A patent/AU2002254935A1/en not_active Abandoned
- 2002-03-08 JP JP2002571053A patent/JP2004526723A/ja active Pending
- 2002-03-08 EP EP02724212A patent/EP1377294B1/de not_active Expired - Lifetime
- 2002-03-08 WO PCT/EP2002/002571 patent/WO2002072094A2/de active IP Right Grant
- 2002-03-08 AT AT02724212T patent/ATE320810T1/de not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005023197D1 (de) | -muscarinrezeptors | |
CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
JP2003503454A5 (ja) | ||
JP2008513510A5 (ja) | ||
WO2008048981A3 (en) | Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
JP2007519649A5 (ja) | ||
NO20044562L (no) | Fremgangsmater for behandling av tarmslyng | |
GEP20135803B (en) | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives | |
WO2008012622A3 (en) | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor | |
LU91867I2 (fr) | Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®) | |
NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
NO20073830L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
JP2010525073A5 (ja) | ||
PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
HRP20120916T1 (hr) | DERIVATI 6H-DIBENZO[b,e]OKSEPINA KAO NESTEROIDNI ANTAGONISTI MINERALOKORTIKOIDNOG RECEPTORA | |
JP2009538898A5 (ja) | ||
CL2007003183A1 (es) | Compuestos biciclicos puenteados; y composicion farmaceutica, util para el tratamiento de trastornos del apetito, diabetes y obesidad entre otros. | |
CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
BRPI0917502A2 (pt) | composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral | |
NO20064808L (no) | Orale matrixformuleringer med licarbazepin | |
WO2008146774A1 (ja) | テトラヒドロイソキノリン-1-オン誘導体またはその塩 | |
JP2015514797A5 (ja) | ||
JP2012502915A5 (ja) | ||
NO20091644L (no) | Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist |